Clinical Trial Search

Primary: Number of Participants Who Achieved Immune Tolerance Induction — 0; 1 participants

Primary: The Percent of Participants Who Achieve Operational Tolerance 52 Weeks After Completion of Immunosuppression Withdrawal. — 16.4 Percent of Participants

Primary: Tolerance, Partial Tolerance, or Treatment Failure — 5; 0; 8; 0 Participants

Primary: The Ability to Withdraw Immunosuppression as Above 24 Months Post-transplant — 6 Participants

Primary: The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion — 4 participants

Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants

Primary: Adverse Events (AEs) as a Measure of Safety and Tolerability — 25; 19; 31; 29 adverse events

Primary: Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) — -0.28; -0.46 pmol/mL — p=0.002

Primary: Successful Withdrawal of Immunosuppressive Therapy — 2 Participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability

Primary: Change of 3-hour Mean Area Under the Curve (AUC) of C-peptide — -0.01; -0.35 pmol/L

Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…

Primary: Change From Baseline in Small Intestine Histology Based on Villous Height to Crypt Depth (Vh:Cd) Ratio — 2.10; 2.30; -0.06; -1.53 ratio — p=0.385

Primary: Change in Peripheral B-cell Tolerance Checkpoints in People With MS Before and After Ocrelizumab Therapy.

Primary: Number of Participants With Successful Withdrawal of Immunosuppression — 2 Participants

Primary: Population Sensitization Threshold in mg Peanut Protein Predicted to Provoke Reactions in 5% of the Peanut-allergic Population — 160; 300 mg

Primary: Proportion of Participants Successfully Withdrawn From Immunosuppression — 0.60 Proportion of participants

Primary: Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B…

Primary: Adverse Events — 2; 2 Serious adverse events

Primary: Total Nasal Symptom Score (TNSS) Area Under the Curve (AUC) — 2.46; 2.81; 3.66; 3.10 Total Nasal Symptom Score * Hour — p=0.314

Primary: Passing the Week 117 DBPCFC to Peanut — 21; 19; 1 participants

Primary: Percentage of Children That Tolerate the Full Challenge — 100; 21 percentage of participants

Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…

Primary: Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year — 71 Percentage of patients

Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants

Primary: Proportion of Participants Who Have Graft Loss or Death — 0.22 Proportion of Participants

Primary: Number of Patients With Renal Allograft Rejection — 5 participant

Primary: Survival Rate at End of 1 Year — 90.9 percentage of participants

Primary: ITI Success — 1; 2; 6; 7 Participants

Primary: Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year — 0.58; 0.429 pmol per mL — p=0.05